Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects

AstraZeneca100 enrolled

Overview

This study is intended to evaluate whether intravenous (iv) esomeprazole (Nexium® ) offers better intragastric acid suppression than iv lansoprazole (Prevacid ®

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

NONE

Enrollment

100

Conditions

Healthy

Interventions

NexiumDRUG

PrevacidDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Participants must be 18-70 years of age * Participants can be male or female * Women that are able to have children must have a negative pregnancy test. Exclusion Criteria: * Involvement in or planning of this study * Participation in another clinical study within 28 days of this one * For women, pregnancy or attempting to become pregnant.

Locations (2)

Research Site

Los Angeles, California, United States

Research Site

Oklahoma City, Oklahoma, United States

Outcomes

Primary Outcomes

The primary objective is to compare the pharmacodynamic efficacy in controlling intragastric pH of esomeprazole 40mg and lansoprazole 30mg on Day 5 of once daily IV administration to healthy volunteers.

Secondary Outcomes

Secondary Outcomes will compare additional efficacy and safety parameters.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.